A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

NCT03482024 · Completed

Last updated 2026-05-28

This study is testing how tirzepatide, a medication, moves through the body in people with kidney problems, including those with severe kidney disease.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 45 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2018-03 · est. completion 2019-08

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT03482024 ↗

Description as written by the study sponsor.

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])
Sponsor	Eli Lilly and Company
Conditions studied	Renal Insufficiency, End Stage Renal Disease
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03482024 ↗